NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET
Company Participants
Chris Smith - Chief Executive Officer
Bill Bonello - Chief Financial Officer
Vishal Sikri - President of our Pharma Services Division, Inivata
Shashi Kulkarni - President of Lab Operations and CSO
Conference Call Participants
Alex Nowak - Craig-Hallam Capital
Andrew Brackmann - William Blair
David Delahunt - Goldman Sachs
Puneet Souda - SVB Securities
Andrew Cooper - Raymond James
Mark Massaro - BTIG
Mason Carrico - Stephens
Tejas Savant - Morgan Stanley
Dan Brennan - Cowen
Mike Matson - Needham & Company
Operator
Good day, ladies and gentlemen, and welcome to the NeoGenomics Third Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.
It is now my pleasure to turn the floor over to your host, Mr. Chris Smith, CEO of NeoGenomics. Chris, the floor is yours.
Chris Smith
Thanks, Jenny, and good morning, everyone. I’d like to welcome you to NeoGenomics’ third quarter 2022 conference call. Joining me for this call from our Fort Myers headquarters are Bill Bonello, our Chief Financial Officer; Vishal Sikri, President of our Pharma Services Division and Inivata; Dr. Shashi Kulkarni, President of Lab Operations and our Chief Scientific Officer.
Before we begin our prepared remarks, Bill will discuss the forward-looking statements and non-GAAP measures used on this call. Bill?
Bill Bonello
This conference call includes forward-looking statements about our 2022 initiatives, 2022 financial outlook, growth opportunities, and anticipated operating results and performance. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.
Additional information regarding these risk factors appears under the heading Forward-Looking Statements in the press release we issued this morning and in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, that is filed with the Securities and Exchange Commission. The forward-looking statements made during this call speak only as of the original date of the call and we undertake no obligation to update or revise any of these statements.
In addition, during the conference call, in order to provide greater transparency regarding our operating performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The non-GAAP financial measures presented should not be considered to be an alternative to financial measures required by GAAP, should not be considered to be measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies.